Prescription drug · ANDA
naratriptan NDC 87063-287
Naratriptan hydrochloride 1 mg/1 · Tablet · Oral · ASCLEMED USA INC.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 87063-287-09 | 87063028709 | 9 TABLET in 1 BLISTER PACK (87063-287-09)Marketed from Aug 7, 2026 | |
| 87063-287-12 | 87063028712 | 12 TABLET in 1 BOTTLE (87063-287-12)Marketed from Aug 7, 2026 | |
| 87063-287-30 | 87063028730 | 30 TABLET in 1 BOTTLE (87063-287-30)Marketed from Aug 7, 2026 | |
| 87063-287-60 | 87063028760 | 60 TABLET in 1 BOTTLE (87063-287-60)Marketed from Aug 7, 2026 | |
| 87063-287-90 | 87063028790 | 90 TABLET in 1 BOTTLE (87063-287-90)Marketed from Aug 7, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- naratriptan
- Generic name (nonproprietary)
- naratriptan
- Active ingredients
- Naratriptan hydrochloride — 1 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- ASCLEMED USA INC.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 200502
- Marketing start
- Listing expires
- Other FDA classes
- Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
- Identifiers
- Product ID 87063-287_586e484f-099e-4e71-e063-6294a90af7d1SPL ID 586e484f-099e-4e71-e063-6294a90af7d1SPL set ID 63ea356f-0895-4540-b242-8e611eacd938RxCUI 311918, 314135UNII 10X8X4P12Z
- Pharmacologic class
- Serotonin-1b and Serotonin-1d Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N487063028709followed by a unit qualifier and the quantityPackage 87063-0287-09. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. Naratriptan Tablets are serotonin (5-HT 1B/1D ) receptor agonists (triptan) indicated for the acute treatment of migraine with or witho…
Excerpt only. Read the full label for complete information.